ArticleTherapeutic advances in chronic disease2022

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores.

Yan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.